Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
P Rada, Á González-Rodríguez, C García-Monzón… - Cell death & …, 2020 - nature.com
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
worldwide. NAFLD stages range from simple steatosis (NAFL) to non-alcoholic …
worldwide. NAFLD stages range from simple steatosis (NAFL) to non-alcoholic …
[HTML][HTML] Mouse models of nonalcoholic steatohepatitis in preclinical drug development
HH Hansen, M Feigh, SS Veidal, KT Rigbolt… - Drug discovery today, 2017 - Elsevier
Highlights•Non-alcoholic steatohepatitis (NASH) is a medical disease of unmet therapeutic
need.•Numerous drugs are in various stages of clinical development for …
need.•Numerous drugs are in various stages of clinical development for …
Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid
Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease,
and is characterized by liver inflammation and fat accumulation. Dietary interventions, such …
and is characterized by liver inflammation and fat accumulation. Dietary interventions, such …
Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling
J Zhong, X He, X Gao, Q Liu, Y Zhao, Y Hong… - Nature …, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) is usually characterized with disrupted bile acid
(BA) homeostasis. However, the exact role of certain BA in NAFLD is poorly understood …
(BA) homeostasis. However, the exact role of certain BA in NAFLD is poorly understood …
[PDF][PDF] Increased liver localization of lipopolysaccharides in human and experimental NAFLD
Background and Aims Lipopolysaccharides (LPS) is increased in nonalcoholic fatty liver
disease (NAFLD), but its relationship with liver inflammation is not defined. Approach and …
disease (NAFLD), but its relationship with liver inflammation is not defined. Approach and …
Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a leading cause of liver disease worldwide.
However, the molecular basis of how benign steatosis progresses to NASH is incompletely …
However, the molecular basis of how benign steatosis progresses to NASH is incompletely …
[HTML][HTML] Animal models of NAFLD from a hepatologist's point of view
D Jahn, S Kircher, HM Hermanns, A Geier - Biochimica et Biophysica Acta …, 2019 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disorder closely linked to obesity,
hyperlipidemia and type 2 diabetes and is increasingly recognized as a major health …
hyperlipidemia and type 2 diabetes and is increasingly recognized as a major health …
Gut microbiota and fermentation-derived branched chain hydroxy acids mediate health benefits of yogurt consumption in obese mice
Meta-analyses suggest that yogurt consumption reduces type 2 diabetes incidence in
humans, but the molecular basis of these observations remains unknown. Here we show …
humans, but the molecular basis of these observations remains unknown. Here we show …
Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-α signaling in obese mice
Liver steatosis is one of the main drivers for the development of whole-body insulin
resistance. Conversely, aerobic training (AT) has been suggested as non-pharmacological …
resistance. Conversely, aerobic training (AT) has been suggested as non-pharmacological …
Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease
Somatic mutations in nonmalignant tissues accumulate with age and injury, but whether
these mutations are adaptive on the cellular or organismal levels is unclear. To interrogate …
these mutations are adaptive on the cellular or organismal levels is unclear. To interrogate …